tiprankstipranks
Trending News
More News >
Medical Data Vision Co.Ltd. (JP:3902)
:3902
Japanese Market

Medical Data Vision Co.Ltd. (3902) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Medical Data Vision Co.Ltd.

(3902)

Rating:43Neutral
Price Target:
Medical Data Vision Co. Ltd. faces significant challenges, primarily due to declining financial performance with negative profitability and cash flow issues. The bearish technical indicators further exacerbate the situation, while a negative P/E ratio indicates poor valuation. The company must address these financial and operational inefficiencies to improve its stock performance.

Medical Data Vision Co.Ltd. (3902) vs. iShares MSCI Japan ETF (EWJ)

Medical Data Vision Co.Ltd. Business Overview & Revenue Model

Company DescriptionMedical Data Vision Co., Ltd. develops, produces, maintains, and sells medical information integration systems in Japan. The company also offers medical data analysis, survey, and consulting services; management consulting services for medical institutions; and medical data services, as well as plans, designs, develops, and operates portal sites. It provides its services to pharmaceutical companies, medical device manufacturer, academia, research institution, and health insurance providers. The company was founded in 2003 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyMedical Data Vision Co., Ltd. makes money primarily through the sale and subscription of its healthcare IT solutions. The company's key revenue streams include licensing fees for its software products, subscription fees for its cloud-based services, and consulting fees for implementation and support services. Additionally, the company may generate income from partnerships with other healthcare technology firms and institutions, as well as from providing data analytics services to healthcare providers looking to optimize their operations and improve patient outcomes.

Medical Data Vision Co.Ltd. Financial Statement Overview

Summary
Medical Data Vision Co. Ltd. faces financial headwinds, with declining revenues and profitability impacting its income statement. While the balance sheet shows resilience due to no leverage, the negative cash flow trends highlight potential liquidity concerns. The company should focus on improving operational efficiency and cash flow management to enhance its financial health.
Income Statement
40
Negative
The company experienced a significant decline in revenue and profitability. The gross profit margin decreased from previous years, and the net profit margin turned negative in 2024, indicating profitability challenges. The EBIT and EBITDA margins also showed substantial deterioration, reflecting operational inefficiencies and financial strain.
Balance Sheet
75
Positive
The balance sheet remains strong with no debt, suggesting financial stability. The equity ratio is solid, indicating a high proportion of assets are funded by equity. However, the decline in stockholders' equity and total assets in 2024 suggests a reduction in financial resources.
Cash Flow
30
Negative
Cash flow metrics reveal significant issues, particularly with negative operating cash flow and free cash flow in 2024. The free cash flow to net income ratio has deteriorated, indicating cash flow constraints. This poses risks to the company's financial flexibility and ability to fund operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.91B6.42B6.10B5.67B4.58B
Gross Profit4.33B5.03B5.03B4.64B3.88B
EBITDA130.00M1.87B1.91B1.73B1.24B
Net Income-791.17M979.13M870.51M1.09B700.22M
Balance Sheet
Total Assets4.75B6.23B4.90B5.53B5.32B
Cash, Cash Equivalents and Short-Term Investments1.35B3.22B2.26B3.22B3.19B
Total Debt0.000.000.000.000.00
Total Liabilities1.59B1.91B1.29B1.33B1.18B
Stockholders Equity3.10B4.25B3.52B4.16B4.10B
Cash Flow
Free Cash Flow-1.03B1.59B857.55M1.06B937.32M
Operating Cash Flow-877.85M1.62B910.79M1.08B964.37M
Investing Cash Flow-592.97M-437.83M-868.75M-26.93M-142.58M
Financing Cash Flow-399.00M-225.26M-979.36M-1.03B-589.64M

Medical Data Vision Co.Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price396.00
Price Trends
50DMA
406.36
Positive
100DMA
415.98
Positive
200DMA
440.93
Negative
Market Momentum
MACD
1.69
Negative
RSI
67.06
Neutral
STOCH
71.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3902, the sentiment is Positive. The current price of 396 is below the 20-day moving average (MA) of 402.30, below the 50-day MA of 406.36, and below the 200-day MA of 440.93, indicating a neutral trend. The MACD of 1.69 indicates Negative momentum. The RSI at 67.06 is Neutral, neither overbought nor oversold. The STOCH value of 71.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3902.

Medical Data Vision Co.Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$12.36T30.1522.80%3.33%17.96%25.65%
79
Outperform
$5.80T29.1620.56%1.36%13.56%12.78%
74
Outperform
$2.52T49.463.22%5.28%19.25%294.48%
70
Outperform
$4.00T34.278.56%0.96%12.40%10.46%
65
Neutral
$6.92T63.871.50%4.49%7.45%-25.77%
51
Neutral
$7.44B0.40-61.90%2.33%17.14%1.55%
43
Neutral
¥16.89B4,465.71
1.60%-7.98%-181.00%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3902
Medical Data Vision Co.Ltd.
433.00
-172.44
-28.48%
JP:7741
HOYA
16,650.00
-2,645.90
-13.71%
JP:4503
Astellas Pharma
1,416.50
-99.06
-6.54%
JP:4519
Chugai Pharmaceutical Co
7,237.00
1,593.08
28.23%
JP:4543
Terumo
2,602.00
7.54
0.29%
JP:4502
Takeda Pharmaceutical Co
4,425.00
393.77
9.77%

Medical Data Vision Co.Ltd. Corporate Events

Medical Data Vision’s Plan to Meet Tokyo Stock Exchange Criteria
Mar 28, 2025

Medical Data Vision Co., Ltd. has announced that it currently does not meet the Tokyo Stock Exchange Prime Market’s criteria for ‘Tradable Shares Market Capitalization’ as of December 31, 2024. The company has devised a compliance plan to meet these criteria by December 31, 2026, and is actively working to enhance its corporate value while engaging with shareholders and stakeholders.

Medical Data Vision Co. Reports Financial Decline but Projects Recovery
Feb 14, 2025

Medical Data Vision Co., Ltd. reported a significant decline in its financial performance for the fiscal year ended December 31, 2024, with a notable drop in net sales and a substantial net loss compared to the previous year. Despite these setbacks, the company forecasts a strong recovery for 2025, anticipating significant growth in net sales and a return to profitability, which suggests an optimistic outlook for future operations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 08, 2025